Aramco CEO Amin Nasser said in London on October 5 that global oil inventories are 'scarily thin' after a seven-month war removed nearly 3 billion barrels of supply, that accessible oil stocks sit near 600 million barrels, and that rebuilding could take two years even after Hormuz fully reopens. The G7 answered with a release of up to 100 million barrels, roughly 1 percent of the 10 billion barrels the world entered the crisis with. Low-cost US producers collect the upside while that cushion stays thin. OXY trades at $57.93 with IV rank at 27 and IV percentile near 30, so the June 2027 65 call is cheap against a thesis with a multi-quarter runway. Beta is minus 0.50, so the position also diversifies a tech-heavy book. Options liquidity is rated 4 of 5. The main risk is a full Hormuz reopening combined with restored OPEC volumes, which would knock crude down and leave the call worthless. Earnings land on November 9 and can move the stock either way.
Options brief, Oct 6, 2026
The daily options brief for this market date: one trade line and thesis per name, and the morning's headlines.
OXY · Bullish
TSM · Bullish
Musk confirmed on October 3 that TSMC is in talks to join Terafab, his Texas chip venture with Tesla, SpaceX and xAI, and TSMC closed at a record $485.80 the next session. Days later, per the FT, BofA, Citi and Morgan Stanley launched a record $60 billion financing to fund Anthropic's lease of Google TPU chips, with about $42 billion backed by Broadcom, whose silicon TSMC fabricates. Both events add demand at the leading edge of the foundry market. TSM IV rank is 8 and IV percentile is under 3, unusually cheap for a stock printing all-time highs, so the June 2027 550 call prices in little upside. The main risk is near term: TSMC reports earnings on October 15, nine days out, and a soft print could send the shares down sharply. The Terafab talks are preliminary, so the premium from that headline can unwind if the deal dissolves. Beta is 1.41 and options liquidity is rated 3.
NKE · Bearish
Nike's October 1 report is the catalyst. Revenue of $11.21 billion missed estimates and fell 4 percent year over year, with Greater China down more than 20 percent for a ninth straight quarterly decline. Management guided FY2027 revenue down high single digits and adjusted EPS to $1.15 to $1.35, below the $1.64 a share the company pays in dividends. The Pace restructuring defers $2.5 billion of savings to fiscal 2031, so the cost cuts provide no near-term earnings support. Shares sit at $33.64 near a 13-year low after a 9 percent post-earnings drop. NKE IV percentile is roughly 30, the cheap end of the range, and the June 2027 expiry spans three more earnings reports of guided declines. Options liquidity is rated 4. The main risk is a bounce: the bear case is crowded, and value buyers, an activist, or a better-than-feared holiday quarter can lift the shares against the fundamentals. Beta of 0.79 means broad market weakness alone will not sink this stock; the declines have to come from Nike itself, and its own guidance says they will.
GOOGL · Bullish
This updates the standing bullish view on GOOGL, with the arms-dealer leg now quantified. The Information reported in May that Anthropic committed $200 billion over five years to Google Cloud for TPU capacity, over 40 percent of Alphabet's disclosed cloud backlog. Google agreed in April to invest up to $40 billion in Anthropic, per CNBC. On October 6 the FT reported a record $60 billion financing led by BofA, Citi and Morgan Stanley to fund Anthropic's TPU leases, with about $42 billion backed by Broadcom. Gemini 4 Argon, launched September 30, ties or beats GPT-6 Astra and Claude Opus 5.5 on 14 of 19 benchmarks, per JPMorgan. GOOGL trades at $345.27 against a 52-week high of $408.61, so the TPU revenue story has room to run. Sentiment on the name is at a euphoric extreme after the Argon launch, so this update is expressed in stock instead of calls. Earnings on November 4 are the main event risk, beta is 1.2, and the FTC probe into frontier labs announced September 30 adds regulatory noise.
Headlines
- alphatau.com/alpha-tau-announces-groundbreaking-interim-results-from-its-u-s-alpha-dart-recurrent-glioblastoma-trial-with-100-local-disease-control-67-complete-response-rate-and-favorable-safety-profile/
- alphatau.com/alpha-tau-completes-patient-enrollment-in-its-u-s-pivotal-skin-cancer-study-advancing-towards-goal-of-fda-approval-of-alpha-dart-to-treat-recurrent-cutaneous-squamous-cell-carcinoma/
- Alpha DaRT Elicits 100% Local Disease Control in Pancreatic Cancer | CancerNetworkPhilip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.www.cancernetwork.com
- www.sec.gov/Archives/edgar/data/1871321/000121390026025174/ea0279271-20f_alpha.htm
- World's Biggest Oil Giant Warns Global Stockpiles Are 'Scarily Thin' and Could Take Two Years to RebuildSaudi Aramco CEO Amin Nasser says oil inventories are 'scarily thin' after Middle East disruptions, with restocking potentially taking two years as Hormuz remains critical.www.ibtimes.co.uk